Merck (MRK) Chief Marketing Officer sells 20,000 shares at about $122

Rhea-AI Filing Summary

Merck & Co., Inc. executive stock sale: Chief Marketing Officer Chirfi Guindo sold 20,000 shares of Merck common stock on February 5, 2026 in an open-market transaction. The weighted average sale price was $121.8838 per share, with individual trades ranging from $121.84 to $121.97.

After this sale, Guindo still directly owns 80,615.127 Merck shares, so he remains a significant internal shareholder. The filing notes that detailed trade prices within the reported range are available on request from Merck, its security holders, or the SEC staff.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guindo Chirfi

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		S		20,000	D	$121.8838(1)	80,615.127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.8400 to $121.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

	/s/ Kelly Grez, as attorney-in-fact for Mr. Chirfi Guindo	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Merck (MRK) report for Chirfi Guindo?

Merck reported that Chief Marketing Officer Chirfi Guindo sold 20,000 shares of Merck common stock on February 5, 2026. The sale was an open-market transaction reported on a Form 4, reflecting a routine insider trade by a senior executive.

At what price did Merck (MRK) executive Chirfi Guindo sell his shares?

Chirfi Guindo sold 20,000 Merck shares at a weighted average price of $121.8838 per share. Individual trades occurred in multiple transactions, with prices ranging from $121.8400 to $121.9700, according to the Form 4 filing’s explanatory footnote.

How many Merck (MRK) shares does Chirfi Guindo still own after the sale?

After selling 20,000 shares, Chirfi Guindo directly owns 80,615.127 shares of Merck common stock. This remaining stake indicates he continues to hold a substantial personal investment in the company despite the disclosed sale.

What role does Chirfi Guindo hold at Merck (MRK) in this Form 4 filing?

In the Form 4, Chirfi Guindo is identified as Merck’s Chief Marketing Officer. The filing classifies him as an officer of the company, which is why his sale of Merck common stock must be reported under SEC insider trading disclosure rules.

How can investors get detailed trade data for Chirfi Guindo’s Merck (MRK) sale?

The filing states that full details of each individual sale price within the $121.8400 to $121.9700 range are available on request. Investors, Merck security holders, or SEC staff can ask Merck or the reporting person for this detailed breakdown.